白癜風(fēng)患者血清及皰液中IL-22、肝及干細(xì)胞生長(zhǎng)因子水平測(cè)定
發(fā)布時(shí)間：2018-08-06 10:49
【摘要】： 目的：檢測(cè)白癜風(fēng)患者血清及皰液中白細(xì)胞介素-22(Interleukin-22, IL-22)、肝細(xì)胞生長(zhǎng)因子(Hepatocyte Growth Factor,HGF)及干細(xì)胞生長(zhǎng)因子(Stem Cell Factor,SCF)水平,并分析處于不同發(fā)病階段及經(jīng)過(guò)治療后不同療效的白癜風(fēng)患者上述因子水平變化情況,探討上述因子在白癜風(fēng)發(fā)病過(guò)程中的可能作用。 方法：收集2008年6月至2009年9月間于青島大學(xué)醫(yī)學(xué)院附屬醫(yī)院皮膚科就診的白癜風(fēng)患者為實(shí)驗(yàn)組,并以我院健康體檢中心的健康人群為對(duì)照組。采用雙抗體夾心酶聯(lián)免疫吸附試驗(yàn)法(ELISA法)對(duì)56例患者及20例健康志愿者血清及其中15例接受表皮移植的患者皮損皰液中IL-22、HGF、SCF因子水平進(jìn)行測(cè)定。同時(shí)采用綜合療法對(duì)全程接受治療的18例患者血清中三種因子水平進(jìn)行監(jiān)測(cè),觀察三種因子的水平變化情況,數(shù)據(jù)采用SPSS3.0軟件進(jìn)行統(tǒng)計(jì)分析。 結(jié)果：進(jìn)展期患者組、穩(wěn)定期患者組、對(duì)照組血清中IL-22水平依次降低,且兩兩組間差異均有統(tǒng)計(jì)學(xué)意義(P均0.05),而患者組與進(jìn)展期患者組及患者組與穩(wěn)定期患者組間血清中IL-22水平差異未見有統(tǒng)計(jì)學(xué)意義(P0.05)。進(jìn)展期患者組血清中HGF水平低于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05),其余各組間HGF水平比較差異均未見有統(tǒng)計(jì)學(xué)意義(P均0.05)�；颊呓M、進(jìn)展期患者組、穩(wěn)定期患者組血清中SCF水平差異均未見統(tǒng)計(jì)學(xué)意義(P均0.05)。接受表皮移植患者皮損皰液中IL-22含量顯著高于供皮區(qū)水平,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。接受表皮移植患者皮損皰液中HGF水平低于供皮區(qū)水平,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。接受表皮移植患者皮損區(qū)皰液SCF水平顯著高于供皮區(qū),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。18例患者經(jīng)系統(tǒng)治療后,療效較好患者血清中IL-22水平與治療前比較下降明顯,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。而療效較差患者血清中IL-22水平差異未見統(tǒng)計(jì)學(xué)意義(P0.05),不同療效患者血清中HGF、SCF水平差異均未見統(tǒng)計(jì)學(xué)意義(P均0.05)。 結(jié)論：IL-22可能在白癜風(fēng)發(fā)病及加重過(guò)程中起重要作用,IL-22水平變化有可能成為預(yù)測(cè)白癜風(fēng)患者病情進(jìn)展及評(píng)價(jià)治療療效的指標(biāo)之一。白癜風(fēng)患者血清及皮損皰液中IL-22、HGF及SCF因子水平異常可能參與了白癜風(fēng)的發(fā)病過(guò)程,白癜風(fēng)患者體內(nèi)HGF及SCF通路可能與白癜風(fēng)的發(fā)病有關(guān),同時(shí)兩條通路可能與IL-22有一定聯(lián)系。
[Abstract]:Objective: to detect the levels of interleukin-22 (IL-22), hepatocyte growth factor (Hepatocyte Growth) and stem cell growth factor (Stem Cell) in serum and bullous fluid of patients with vitiligo. The changes of these factors in patients with vitiligo at different stages and after treatment were analyzed, and the possible role of these factors in the pathogenesis of vitiligo was discussed. Methods: the patients with vitiligo were collected from June 2008 to September 2009 in the Department of Dermatology affiliated Hospital of Qingdao University Medical College as the experimental group and the healthy people in the health examination center of our hospital as the control group. Double antibody sandwich enzyme linked immunosorbent assay (ELISA) was used to determine the level of IL-22 HGF factor in the bullous fluid of 56 patients and 20 healthy volunteers and 15 of them received epidermal transplantation. At the same time, the serum levels of three factors in 18 patients were monitored by comprehensive therapy, and the changes of the three factors were observed. The data were analyzed by SPSS3.0 software. Results: the serum levels of IL-22 in advanced patients, stable patients and control groups decreased in turn. The difference between the two groups was statistically significant (P 0.05), but there was no significant difference in serum IL-22 levels between the patients group and the advanced group and between the patient group and the stable group (P0.05). The serum HGF level in the advanced group was lower than that in the control group (P0.05), but there was no significant difference in the HGF level among the other groups (P0.05). There was no significant difference in serum SCF levels among patients, advanced patients and stable patients (P < 0. 05). The content of IL-22 in epidermal graft patients with blister fluid was significantly higher than that in donor skin area, the difference was statistically significant (P0.05). The level of HGF in epidermis grafts was lower than that in donor area (P0.05). The SCF level of bullous fluid in epidermal transplant patients was significantly higher than that in donor skin area (P0.05). After systemic treatment, the serum IL-22 level of 18 patients with better curative effect was significantly lower than that of before treatment (P0.05). There was no significant difference in serum IL-22 levels in patients with poor efficacy (P0.05), and no significant difference in serum IL-22 levels in patients with different therapeutic effects (P0.05). Conclusion the level of IL-22 may play an important role in the pathogenesis and aggravation of vitiligo. The changes of IL-22 level may be one of the indexes to predict the progression of vitiligo and evaluate the therapeutic effect. The abnormal levels of IL-22 HGF and SCF in serum and bullous fluid may be involved in the pathogenesis of vitiligo. The HGF and SCF pathways in vitiligo patients may be related to the pathogenesis of vitiligo, and the two pathways may be related to IL-22.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2010
【分類號(hào)】：R758.41
本文編號(hào)：2167500
[Abstract]:Objective: to detect the levels of interleukin-22 (IL-22), hepatocyte growth factor (Hepatocyte Growth) and stem cell growth factor (Stem Cell) in serum and bullous fluid of patients with vitiligo. The changes of these factors in patients with vitiligo at different stages and after treatment were analyzed, and the possible role of these factors in the pathogenesis of vitiligo was discussed. Methods: the patients with vitiligo were collected from June 2008 to September 2009 in the Department of Dermatology affiliated Hospital of Qingdao University Medical College as the experimental group and the healthy people in the health examination center of our hospital as the control group. Double antibody sandwich enzyme linked immunosorbent assay (ELISA) was used to determine the level of IL-22 HGF factor in the bullous fluid of 56 patients and 20 healthy volunteers and 15 of them received epidermal transplantation. At the same time, the serum levels of three factors in 18 patients were monitored by comprehensive therapy, and the changes of the three factors were observed. The data were analyzed by SPSS3.0 software. Results: the serum levels of IL-22 in advanced patients, stable patients and control groups decreased in turn. The difference between the two groups was statistically significant (P 0.05), but there was no significant difference in serum IL-22 levels between the patients group and the advanced group and between the patient group and the stable group (P0.05). The serum HGF level in the advanced group was lower than that in the control group (P0.05), but there was no significant difference in the HGF level among the other groups (P0.05). There was no significant difference in serum SCF levels among patients, advanced patients and stable patients (P < 0. 05). The content of IL-22 in epidermal graft patients with blister fluid was significantly higher than that in donor skin area, the difference was statistically significant (P0.05). The level of HGF in epidermis grafts was lower than that in donor area (P0.05). The SCF level of bullous fluid in epidermal transplant patients was significantly higher than that in donor skin area (P0.05). After systemic treatment, the serum IL-22 level of 18 patients with better curative effect was significantly lower than that of before treatment (P0.05). There was no significant difference in serum IL-22 levels in patients with poor efficacy (P0.05), and no significant difference in serum IL-22 levels in patients with different therapeutic effects (P0.05). Conclusion the level of IL-22 may play an important role in the pathogenesis and aggravation of vitiligo. The changes of IL-22 level may be one of the indexes to predict the progression of vitiligo and evaluate the therapeutic effect. The abnormal levels of IL-22 HGF and SCF in serum and bullous fluid may be involved in the pathogenesis of vitiligo. The HGF and SCF pathways in vitiligo patients may be related to the pathogenesis of vitiligo, and the two pathways may be related to IL-22.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2010
【分類號(hào)】：R758.41
【參考文獻(xiàn)】
相關(guān)期刊論文 前8條
1 孫越,韓菁,朱光斗;白癜風(fēng)150例家系調(diào)查[J];臨床皮膚科雜志;2000年03期
2 王曉華,陳曉棟;白癜風(fēng)48例血清鋅銅含量分析[J];南通醫(yī)學(xué)院學(xué)報(bào);1996年02期
3 李宗平,朱美蓉;白癜風(fēng)患者血清中微量元素Cu含量測(cè)定[J];上海預(yù)防醫(yī)學(xué)雜志;2001年05期
4 高天文,李強(qiáng),李春英,李志強(qiáng),王秋楓;白癜風(fēng)2008例臨床分析[J];中國(guó)皮膚性病學(xué)雜志;2002年05期
5 王巖,肖毅,張曉東,趙玉銘,劉永學(xué),宋芳吉,陳洪鐸;有無(wú)家族史白癜風(fēng)與HLA-Ⅰ類抗原的關(guān)聯(lián)性研究[J];中國(guó)皮膚性病學(xué)雜志;2001年03期
6 涂彩霞,林熙然,殷峰;白癜風(fēng)患者血清及皮膚組織液銅鋅含量測(cè)定[J];中國(guó)皮膚性病學(xué)雜志;1991年01期
7 顧勁松,涂彩霞,譚雪晶,谷玲,林熙然;白癜風(fēng)患者血清白介素、腫瘤壞死因子α及粒細(xì)胞-巨噬細(xì)胞集落刺激因子檢測(cè)[J];中華皮膚科雜志;2003年02期
8 田艷麗;李春英;王剛;高天文;盧濤;李淼;;In-cellPCR技術(shù)擴(kuò)增白癜風(fēng)自身抗體基因[J];中華皮膚科雜志;2006年01期
，本文編號(hào)：2167500
本文鏈接：http://sikaile.net/yixuelunwen/pifb/2167500.html
最近更新
教材專著
